{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-120141","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.043460+00:00","generated_at":"2026-05-16T13:30:44.403202+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rhythm Pharma reports positive Phase 2 setmelanotide data in PWS; plans Phase 3","bullets":["18 patients enrolled; 17 remain on therapy; safety consistent with known profile.","6 of 8 patients at Month 3 achieved BMI reduction; 3 of 5 at Month 6 saw BMI reduction.","6 of 7 evaluable patients at Month 3 had meaningful hyperphagia (HQ-CT) score reduction.","Company plans to advance setmelanotide into Phase 3 registrational trial in PWS.","Initiated Phase 1 Part D of weekly MC4R agonist RM-718 in up to 20 PWS patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-120141","json":"https://secwatch.observer/filing/0001104659-25-120141.json","markdown":"https://secwatch.observer/filing/0001104659-25-120141.md","text":"https://secwatch.observer/filing/0001104659-25-120141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465925120141/0001104659-25-120141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465925120141/rytm-20251211x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:30:44.403202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}